ICU
SeaStar Medical Holding Corporation
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-19/100
Last price
3.19
▼ 0.36 (10.14%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
3.55
Day high
3.50
Day low
3.07
Volume
292.77K
Market cap
$14.06M
P/E (TTM)
—
52W range
2.07 – 7.35
Trailing performance
Returnvs SPY
1W
-10.39%
-12.3%
1M
+7.05%
+5.9%
3M
-37.20%
-41.7%
6M
-23.50%
-41.7%
YTD
+32.92%
+18.7%
1Y
-50.85%
-67.3%
3Y
-95.17%
-177.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ICU open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
512.21K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | MESSINGER MICHAEL Chief Financial Officer |
BUY | 750 | $2.45K | Direct |
| Jul 1, 26 | VAN HEEL KENNETH J. Director |
STOCK | 4.00K | $0 | Direct |
| Jul 1, 26 | SCHLORFF ERIC Chief Executive Officer |
STOCK | 10.29K | $0 | Direct |
| Jul 1, 26 | CHUNG KEVIN Officer |
STOCK | 7.20K | $0 | Direct |
| Jul 1, 26 | NEUMAN JOHN Director |
STOCK | 4.00K | $0 | Direct |
| Jul 1, 26 | BAIRD JENNIFER A Director |
STOCK | 4.00K | $0 | Direct |
| Jul 1, 26 | VINCENT BERNADETTE N Director |
STOCK | 4.00K | $0 | Direct |
| Feb 6, 26 | VAN HEEL KENNETH J. Director |
STOCK | 3.00K | $0 | Direct |
| Feb 6, 26 | TOWNE BRADFORD K Officer |
STOCK | 7.50K | $0 | Direct |
| Feb 6, 26 | SCHLORFF ERIC Chief Executive Officer |
STOCK | 30.00K | $0 | Direct |
| Feb 6, 26 | CHUNG KEVIN Officer |
STOCK | 15.00K | $0 | Direct |
| Feb 6, 26 | NEUMAN JOHN Director |
STOCK | 3.00K | $0 | Direct |
| Feb 6, 26 | BAIRD JENNIFER A Director |
STOCK | 3.00K | $0 | Direct |
| Feb 6, 26 | VINCENT BERNADETTE N Director |
STOCK | 3.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAIRD JENNIFER A |
Director | 10.62K | Stock Award(Grant) |
CHUNG KEVIN |
Officer | 28.02K | Stock Award(Grant) |
MESSINGER MICHAEL |
Chief Financial Officer | 2.50K | Purchase |
NEUMAN JOHN |
Director | 16.20K | Stock Award(Grant) |
SCHLORFF ERIC |
Chief Executive Officer | 50.14K | Stock Award(Grant) |
TOWNE BRADFORD K |
Officer | 9.05K | Stock Award(Grant) |
VAN HEEL KENNETH J. |
Director | 11.94K | Stock Award(Grant) |
VINCENT BERNADETTE N |
Director | 8.20K | Stock Award(Grant) |
Fundamentals
Market cap$14.06M
Enterprise value$7.23M
Revenue (TTM)$1.71M
Gross profit$1.59M
EBITDA—
Net income$-13.63M
EPS (TTM)$-2.72
Free cash flow$-9.14M
Total cash$6.96M
Total debt$134.00K
Book value / share$1.01
Shares outstanding4.41M
Float4.36M
Short % of float2.78%
Dividend yield0.00%
Beta (5Y)-1.07
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.24
PEG ratio—
Price / sales—
Price / book3.16
EV / revenue4.22
EV / EBITDA—
Gross margin92.64%
Operating margin-616.42%
Profit margin0.00%
Return on equity-356.87%
Return on assets-102.67%
Debt / equity3.12
Current ratio1.89
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.23M | $135.00K | $0 | $0 | +814.1% |
| Operating revenue | $1.23M | $135.00K | $0 | $0 | +814.1% |
| Cost of revenue | $53.00K | $0 | $0 | — | — |
| Gross profit | $1.18M | $135.00K | $0 | — | +774.8% |
| Research & development | $7.52M | $9.11M | $5.97M | $2.50M | -17.4% |
| Selling, general & admin | $5.84M | $8.87M | $8.24M | $6.92M | -34.2% |
| Total operating expense | $13.36M | $17.98M | $14.21M | $11.61M | -25.7% |
| Operating income | -$12.18M | -$17.84M | -$14.21M | -$11.61M | +31.8% |
| Net interest income | -$4.00K | -$143.00K | -$1.08M | -$630.00K | +97.2% |
| Pre-tax income | -$12.15M | -$24.83M | -$26.23M | -$12.19M | +51.1% |
| Tax provision | $3.00K | $3.00K | $0 | $1.00K | 0.0% |
| Net income | -$12.15M | -$24.83M | -$26.23M | -$12.19M | +51.1% |
| Net income to common | -$12.15M | -$24.83M | -$26.23M | -$12.19M | +51.1% |
| Basic EPS | -5.86 | -66.30 | -302.60 | -700.00 | +91.2% |
| Diluted EPS | -5.86 | -66.30 | -302.60 | -700.00 | +91.2% |
| EBIT | -$12.12M | -$24.58M | -$25.15M | -$11.56M | +50.7% |
| EBITDA | -$12.12M | -$24.58M | -$25.15M | -$11.56M | +50.7% |
| Basic shares | 2.07M | 374.36K | 86.68K | 32.84K | +453.8% |
| Diluted shares | 2.07M | 374.36K | 86.68K | 32.84K | +453.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.98M | $1.82M | $176.00K | $47.00K | — | +558.6% |
| Cash & short-term investments | $11.98M | $1.82M | $176.00K | $47.00K | — | +558.6% |
| Accounts receivable | $237.00K | $112.00K | $0 | — | — | +111.6% |
| Inventory | $66.00K | $0 | — | — | $0 | — |
| Total current assets | $13.58M | $3.77M | $2.31M | $1.52M | — | +260.6% |
| Total assets | $14.16M | $4.66M | $3.51M | $3.04M | — | +204.0% |
| Total current liabilities | $3.74M | $6.84M | $13.05M | $16.15M | — | -45.3% |
| Current debt | $525.00K | $574.00K | $4.74M | $1.18M | — | -8.5% |
| Long-term debt | — | — | $4.34M | $7.65M | $244.00K | — |
| Total debt | $525.00K | $574.00K | $9.08M | $8.83M | — | -8.5% |
| Total liabilities | $3.74M | $6.84M | $17.38M | $23.80M | — | -45.3% |
| Retained earnings | -$151.71M | -$139.56M | -$114.73M | -$88.50M | — | -8.7% |
| Shareholder equity | $10.42M | -$2.18M | -$13.87M | -$20.76M | — | +577.1% |
| Working capital | $9.84M | -$3.08M | -$10.74M | -$14.63M | — | +419.9% |
| Net tangible assets | $10.42M | -$2.18M | -$13.87M | -$20.76M | — | +577.1% |
| Shares issued | 3.84M | 597.72K | 190.46K | 50.80K | — | +543.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$12.15M | -$24.83M | -$26.23M | -$12.19M | +51.1% |
| Stock-based compensation | $624.00K | $887.00K | $1.93M | $1.31M | -29.7% |
| Change in working capital | -$2.36M | $992.00K | $2.88M | $2.55M | -337.6% |
| Operating cash flow | -$13.60M | -$16.01M | -$10.29M | -$7.79M | +15.0% |
| Financing cash flow | $23.76M | $17.65M | $10.41M | $7.33M | +34.6% |
| Free cash flow | -$13.60M | -$16.01M | -$10.29M | -$7.79M | +15.0% |
| End cash position | $11.98M | $1.82M | $176.00K | $47.00K | +558.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $615.00K | $495.00K | $420.00K | $183.00K | $338.00K | +24.2% |
| Operating revenue | $615.00K | $495.00K | $420.00K | $183.00K | $338.00K | +24.2% |
| Cost of revenue | $54.00K | $46.00K | $12.00K | $14.00K | $27.00K | +17.4% |
| Gross profit | $561.00K | $449.00K | $408.00K | $169.00K | $311.00K | +24.9% |
| Research & development | $2.52M | $2.34M | $2.20M | $1.85M | $1.04M | +7.5% |
| Selling, general & admin | $1.83M | $1.71M | $1.22M | $1.90M | $1.03M | +7.3% |
| Total operating expense | $4.35M | $4.05M | $3.42M | $3.75M | $2.07M | +7.4% |
| Operating income | -$3.79M | -$3.60M | -$3.02M | -$3.58M | -$1.76M | -5.2% |
| Net interest income | $61.00K | $85.00K | $112.00K | $107.00K | -$262.00K | -28.2% |
| Pre-tax income | -$3.73M | -$3.52M | -$2.90M | -$3.47M | -$2.00M | -6.0% |
| Tax provision | $0 | $3.00K | $0 | $0 | $0 | -100.0% |
| Net income | -$3.73M | -$3.52M | -$2.90M | -$3.47M | -$2.00M | -5.9% |
| Net income to common | -$3.73M | -$3.52M | -$2.90M | -$3.47M | -$2.00M | -5.9% |
| Basic EPS | -0.91 | -0.90 | -0.80 | -1.30 | -1.80 | -1.1% |
| Diluted EPS | -0.91 | -0.90 | -0.80 | -1.30 | -1.80 | -1.1% |
| EBIT | -$3.72M | -$3.51M | -$2.89M | -$3.47M | -$1.99M | -6.0% |
| EBITDA | -$3.72M | -$3.51M | -$2.89M | -$3.47M | -$1.99M | -6.0% |
| Basic shares | 4.08M | 3.92M | 3.62M | 2.64M | 1.13M | +4.2% |
| Diluted shares | 4.08M | 3.92M | 3.62M | 2.64M | 1.13M | +4.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6.96M | $9.35M | $11.98M | $13.76M | $6.30M | — | -25.6% |
| Cash & short-term investments | $6.96M | $9.35M | $11.98M | $13.76M | $6.30M | — | -25.6% |
| Accounts receivable | $208.00K | $179.00K | $237.00K | $221.00K | $217.00K | — | +16.2% |
| Inventory | $77.00K | $57.00K | $66.00K | $83.00K | $77.00K | — | +35.1% |
| Total current assets | $8.23M | $10.76M | $13.58M | $14.87M | $7.65M | — | -23.6% |
| Total assets | $8.65M | $11.26M | $14.16M | $15.53M | $8.38M | — | -23.2% |
| Total current liabilities | $4.35M | $3.95M | $3.74M | $4.07M | $5.04M | — | +10.3% |
| Current debt | $134.00K | $331.00K | $525.00K | — | — | $363.00K | -59.5% |
| Total debt | $134.00K | $331.00K | $525.00K | — | — | $363.00K | -59.5% |
| Total liabilities | $4.35M | $3.95M | $3.74M | $4.07M | $5.04M | — | +10.3% |
| Retained earnings | -$158.97M | -$155.24M | -$151.71M | -$148.81M | -$145.34M | — | -2.4% |
| Shareholder equity | $4.30M | $7.32M | $10.42M | $11.46M | $3.34M | — | -41.3% |
| Working capital | $3.88M | $6.82M | $9.84M | $10.81M | $2.60M | — | -43.1% |
| Net tangible assets | $4.30M | $7.32M | $10.42M | $11.46M | $3.34M | — | -41.3% |
| Shares issued | 4.26M | 3.99M | 3.84M | 3.41M | 1.73M | — | +6.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$3.73M | -$3.52M | -$2.90M | -$3.47M | -$2.00M | -5.9% |
| Stock-based compensation | -$99.00K | $91.00K | $70.00K | $290.00K | $97.00K | -208.8% |
| Change in working capital | $827.00K | $663.00K | -$1.26M | -$662.00K | -$1.39M | +24.7% |
| Operating cash flow | -$2.99M | -$2.76M | -$4.09M | -$3.84M | -$3.01M | -8.4% |
| Financing cash flow | $605.00K | $129.00K | $2.31M | $11.30M | $4.01M | +369.0% |
| Free cash flow | -$2.99M | -$2.76M | -$4.09M | -$3.84M | -$3.01M | -8.4% |
| End cash position | $6.96M | $9.35M | $11.98M | $13.76M | $6.30M | -25.6% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.97 | -0.91 | +6.2% |
| Mar 2026 | -0.83 | -0.90 | -9.1% |
| Dec 2025 | -1.02 | -0.80 | +21.2% |
| Sep 2025 | -1.50 | -1.30 | +13.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.95 | 1 | $500.00K | +173.2% |
| Next quarter | -0.89 | 1 | $500.00K | +19.0% |
| Current year | -3.66 | 1 | $2.00M | +62.1% |
| Next year | -2.34 | 2 | $2.93M | +46.6% |
Analyst targets & ownership
Mean target$10.00
High target$12.00
Low target$8.00
Implied upside213.48%
Analyst count2
ConsensusNONE
Strong buy / Buy1 / 0
Hold0
Sell / Strong sell0 / 0
Held by insiders11.62%
Held by institutions7.62%
Institutions holding22
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.65
-12.53% from price
SMA 20
3.45
-7.60% from price
SMA 50
3.30
-3.30% from price
SMA 100
3.53
-9.59% from price
SMA 200
3.28
-2.85% from price
EMA 12
3.60
-11.45% from price
EMA 26
3.48
-8.26% from price
EMA 50
3.45
-7.54% from price
RSI (14)
45.6
Neutral
MACD (12,26,9)
0.13
Hist 0.02
ATR (14)
0.44
13.70% of price
Realised vol 30D
123.1%
Annualised
Bollinger upper
4.21
20, 2σ
Bollinger lower
2.70
20, 2σ
50 / 200 cross
Golden
3.30 vs 3.28
Trend bias
Below 200
-2.85%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.05
More volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
123.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-66.5%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
0.44
13.70% of price
Beta (reported)
-1.07
5Y monthly, from filing
Short interest
Shares short
121.69K
Prior 121.69K
Change vs prior
-0.0%
Shorts covering
% of float
2.78%
Normal
% of shares out
2.76%
Against total outstanding
Days to cover
2.6
Liquid
Float
4.36M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 14, 26 | Maxim Group | MAINTAINED | Buy | Buy |
| Apr 20, 23 | Maxim Group | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:10
Split dateJan 5, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Corporate Changes & Voting Matters
8-K · 2026-08-12
Offering Registrations
S-8 · 2026-07-21
Corporate Changes & Voting Matters
8-K · 2026-07-01
Corporate Changes & Voting Matters
8-K/A · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-05-13
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-08
Headlines
Top Midday Decliners
MT Newswires · 2d ago
SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds
GlobeNewswire · 2d ago
SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
GlobeNewswire · 5d ago
New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)
GlobeNewswire · 6d ago
SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
GlobeNewswire · 8d ago
SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy
GlobeNewswire · 13d ago
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 27d ago
ICU: Continued Revenue Growth for QUELIMMUNE®
Zacks Small Cap Research · 51d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.